Please ensure Javascript is enabled for purposes of website accessibility

Up 70%! It Was Worth the Wait

By Brian Orelli, PhD - Updated Apr 6, 2017 at 11:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Momenta restarted.

It took long enough, but the wait was worth it.

Motley Fool Rule Breakers recommended Momenta Pharmaceuticals (Nasdaq: MNTA) to subscribers back in the September 2006 issue. Nearly four years later, the investment paid off with shares up over 70% today thanks to a Food and Drug Administration approval of its generic version of sanofi-aventis' (NYSE: SNY) Lovenox.

Normally the approval of a generic drug wouldn't trigger that kind of response, but this is no ordinary generic. Sanofi sold 1.8 billion Euros worth of Lovenox in the U.S. last year, which translates into about $2.3 billion at today's exchange rate.

More importantly, Lovenox is a fairly hard drug to make. That's the reason the FDA took so darn long to approve the drug, but the complexity provides some protection from competition. Both Teva Pharmaceuticals (Nasdaq: TEVA) and Amphastar Pharmaceuticals have applications pending with the FDA, but so far, neither has announced an approval.

Novartis (NYSE: NVS), Momenta's commercialization partner, plans to launch the drug soon. You can expect that with no other generic competition, the price will be fairly close to the price of brand-name Lovenox.

How long the competition-free period remains is very important because it'll affect not only the price of the generic drug, but also Momenta's share of the revenue. If Momenta and Novartis' product is the only generic on the market, Momenta gets a profit share of between 40% and 50%. If other competitors make it to market, Momenta only gets a royalty in the high single-digit to low double-digit.

Looking ahead for Momenta, its first FDA approval is an endorsement of the company's technology of characterizing and copying complex molecules. In addition to generic Lovenox and helping the FDA sort out Baxter's (NYSE: BAX) heparin contamination issue, the company is working on a generic version of Teva's Copaxone, another highly complex drug.

Hopefully investors won't have to wait nearly as long for Momenta's second approval.

You can read the original recommendation of Momenta and see the analysts' current opinion by grabbing a 30-day trial subscription to the Motley Fool Rule Breakers newsletter. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Novartis is a Motley Fool Global Gains choice. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$49.71 (1.08%) $0.53
Novartis AG Stock Quote
Novartis AG
NVS
$85.57 (0.40%) $0.34
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$10.69 (5.63%) $0.57
Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.
MNTA
Baxter International Inc. Stock Quote
Baxter International Inc.
BAX
$58.59 (1.17%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.